- Home
- SCLX vs RMAX Comparison
SCLX vs RMAX Comparison
Compare SCLX & RMAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCLX
- RMAX
- Stock Information
- Founded
- SCLX 2011
- RMAX 1973
- Country
- SCLX United States
- RMAX United States
- Employees
- SCLX N/A
- RMAX N/A
- Industry
- SCLX Biotechnology: Pharmaceutical Preparations
- RMAX Real Estate
- Sector
- SCLX Health Care
- RMAX Finance
- Exchange
- SCLX Nasdaq
- RMAX Nasdaq
- Market Cap
- SCLX 139.3M
- RMAX 151.2M
- IPO Year
- SCLX N/A
- RMAX 2013
- Fundamental
- Price
- SCLX $15.30
- RMAX $7.64
- Analyst Decision
- SCLX Hold
- RMAX Hold
- Analyst Count
- SCLX 1
- RMAX 1
- Target Price
- SCLX N/A
- RMAX $9.00
- AVG Volume (30 Days)
- SCLX 140.1K
- RMAX 173.5K
- Earning Date
- SCLX 08-13-2025
- RMAX 10-30-2025
- Dividend Yield
- SCLX N/A
- RMAX N/A
- EPS Growth
- SCLX N/A
- RMAX N/A
- EPS
- SCLX N/A
- RMAX 0.62
- Revenue
- SCLX $40,360,000.00
- RMAX $292,931,000.00
- Revenue This Year
- SCLX $89.26
- RMAX N/A
- Revenue Next Year
- SCLX $203.95
- RMAX $0.94
- P/E Ratio
- SCLX N/A
- RMAX $12.42
- Revenue Growth
- SCLX N/A
- RMAX N/A
- 52 Week Low
- SCLX $3.60
- RMAX $6.90
- 52 Week High
- SCLX $34.27
- RMAX $14.31
- Technical
- Relative Strength Index (RSI)
- SCLX 42.42
- RMAX 35.39
- Support Level
- SCLX $17.28
- RMAX $7.44
- Resistance Level
- SCLX $19.56
- RMAX $7.82
- Average True Range (ATR)
- SCLX 1.97
- RMAX 0.25
- MACD
- SCLX -0.02
- RMAX -0.00
- Stochastic Oscillator
- SCLX 3.68
- RMAX 12.47
About SCLX Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.
About RMAX RE/MAX Holdings Inc.
RE/MAX Holdings Inc operates as a franchisor of real estate brokerage services. It recruits and retains agents and sells franchises. The company's operating segments include Real Estate, Mortgage, Marketing Funds, and Others. It generates maximum revenue from the Real Estate segment.